Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase II, Open-label, Randomized Clinical Trial of Panitumumab Plus Gemcitabine and Oxaliplatin (GEMOX) Versus GEMOX Alone as First Line Treatment in Advanced Biliary Tract Adenocarcinoma

NCT01389414 is registered in ClinicalTrials.gov with Prof. Massimo Aglietta as lead sponsor.

NCT NCT01389414
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01389414 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase II, Open-label, Randomized Clinical Trial of Panitumumab Plus Gemcitabine and Oxaliplatin (GEMOX) Versus GEMOX Alone as First Line Treatment in Advanced Biliary Tract Adenocarcinoma
Lead sponsor
Prof. Massimo Aglietta
Phase
Phase 2
Overall status
Completed
Start date
May 31, 2010
Completion date
May 31, 2015
Enrollment
89 (actual)
Sites
12

Conditions

As the registry lists them; a condition with its own page is linked.

biliary carcinoma